© 1995 American Heart Association, Inc.
Articles |
Atherosclerotic Disease in Marked Hyperalphalipoproteinemia
Combined Reduction of Cholesteryl Ester Transfer Protein and Hepatic Triglyceride Lipase
From the Second Department of Internal Medicine, Osaka University Medical School, Suita, and the First Department of Internal Medicine, Hiroshima University School of Medicine, Minami-ku (Y.K., K. Hayashi), Japan.
Correspondence to Ken-ichi Hirano, MD, PhD, Section of Gastroenterology, Department of Medicine, University of Chicago, 5841 S Maryland Ave, Chicago, IL 60637.
Abstract Hyperalphalipoproteinemia (HALP) has been regarded
as a beneficial state accompanied by a longevity syndrome. However, we
reported the cases of markedly hyperalphalipoproteinemic subjects with
juvenile corneal opacification. These patients had reduced
postheparin hepatic triglyceride lipase (HTGL)
activities, and one of them has recently been identified to be
homozygous for a missense mutation in exon 15 (D442: G) in the
cholesteryl ester transfer protein (CETP) gene. In the current study,
to elucidate the clinical significance of and atherogenicity in marked
HALP, we determined the incidence of atherosclerotic
cardiovascular disease (ACD) in patients with marked
HALP and characterized the lipoprotein abnormalities in those who had
ACD, focusing especially on CETP and HTGL. The subjects were 201
patients (111 males and 90 females) with marked HALP (
2.58 mmol/L
[100 mg/dL]), 67% of whom were demonstrated to have the CETP gene
mutations in the intron 14 splice donor site or in exon 15. Their mean
age was 54±15 years. Plasma levels of total cholesterol,
HDL cholesterol, and triglyceride in all
subjects were 6.28±1.78, 3.15±0.90, and 1.08±0.53 mmol/L,
respectively. Ten of the male patients (9.0%) and two of the female
patients (2.2%) had apparent ACD such as myocardial infarction, angina
pectoris, and peripheral vascular diseases. Ten patients
with HALP who had ACD were identified to be heterozygotes for CETP
deficiency. To further clarify the characteristics of marked HALP in
patients with ACD, we compared the plasma lipids, lipoproteins, CETP,
and HTGL activities between heterozygotes for CETP deficiency who were
with and without ACD. There was no significant difference in plasma
lipids, lipoproteins, and CETP between the two groups, whereas HTGL
activities were significantly lower in the heterozygotes for CETP
deficiency with ACD than in the heterozygotes without ACD and in
control subjects. These results suggest that marked HALP may not always
be a beneficial state and that people who are heterozygotes for CETP
deficiency and who have low HTGL may be susceptible to ACD.
Key Words: atherosclerosis • cholesteryl ester transfer protein • hepatic triglyceride lipase • reverse cholesterol transport • hyperalphalipoproteinemia
This article has been cited by other articles:
 |
|
 |
|
  S. J. Nicholls, E. M. Tuzcu, D. M. Brennan, J.-C. Tardif, and S. E. Nissen Cholesteryl Ester Transfer Protein Inhibition, High-Density Lipoprotein Raising, and Progression of Coronary Atherosclerosis: Insights From ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation) Circulation, December 9, 2008; 118(24): 2506 - 2514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Regieli, J. W. Jukema, D. E. Grobbee, J. J.P. Kastelein, J. A. Kuivenhoven, A. H. Zwinderman, Y. van der Graaf, M. L. Bots, and P. A. Doevendans CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction Eur. Heart J., November 2, 2008; 29(22): 2792 - 2799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Hime, A. S. Black, J. J. Bulgrien, and L. K. Curtiss Leukocyte-derived hepatic lipase increases HDL and decreases en face aortic atherosclerosis in LDLr-/- mice expressing CETP J. Lipid Res., October 1, 2008; 49(10): 2113 - 2123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Van Eck, D. Ye, R. B. Hildebrand, J. Kar Kruijt, W. de Haan, M. Hoekstra, P. C.N. Rensen, C. Ehnholm, M. Jauhiainen, and T. J.C. Van Berkel Important Role for Bone Marrow-Derived Cholesteryl Ester Transfer Protein in Lipoprotein Cholesterol Redistribution and Atherosclerotic Lesion Development in LDL Receptor Knockout Mice Circ. Res., March 16, 2007; 100(5): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tall, L. Yvan-Charvet, and N. Wang The Failure of Torcetrapib: Was it the Molecule or the Mechanism? Arterioscler. Thromb. Vasc. Biol., February 1, 2007; 27(2): 257 - 260. [Full Text] [PDF]
|
|
|
|
|
|
P. K. Shah Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease Eur. Heart J., January 1, 2007; 28(1): 5 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. C. McPherson, I. S. Young, B. McKibben, and J. McEneny High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation J. Lipid Res., January 1, 2007; 48(1): 86 - 95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Barter and J. J.P. Kastelein Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease J. Am. Coll. Cardiol., February 7, 2006; 47(3): 492 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. de Grooth, A. H. E. M. Klerkx, E. S. G. Stroes, A. F. H. Stalenhoef, J. J. P. Kastelein, and J. A. Kuivenhoven A review of CETP and its relation to atherosclerosis J. Lipid Res., November 1, 2004; 45(11): 1967 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Santamarina-Fojo, H. Gonzalez-Navarro, L. Freeman, E. Wagner, and Z. Nong Hepatic Lipase, Lipoprotein Metabolism, and Atherogenesis Arterioscler. Thromb. Vasc. Biol., October 1, 2004; 24(10): 1750 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Wolfe and D. J. Rader Cholesteryl Ester Transfer Protein and Coronary Artery Disease: An Observation With Therapeutic Implications Circulation, September 14, 2004; 110(11): 1338 - 1340. [Full Text] [PDF]
|
|
|
|
|
|
J. D. Curb, R. D. Abbott, B. L. Rodriguez, K. Masaki, R. Chen, D. S. Sharp, and A. R. Tall A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly J. Lipid Res., May 1, 2004; 45(5): 948 - 953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Cuchel and D. J. Rader Genetics of Increased HDL Cholesterol Levels: Insights Into the Relationship Between HDL Metabolism and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., October 1, 2003; 23(10): 1710 - 1712. [Full Text] [PDF]
|
|
|
|
|
|
W. Le Goff, M. Guerin, M. J. Chapman, and J. Thillet A CYP7A promoter binding factor site and Alu repeat in the distal promoter region are implicated in regulation of human CETP gene expression J. Lipid Res., May 1, 2003; 44(5): 902 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Jansen, A. J. M. Verhoeven, and E. J. G. Sijbrands Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res., September 1, 2002; 43(9): 1352 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Dugi, K. Brandauer, N. Schmidt, B. Nau, J. G. Schneider, S. Mentz, T. Keiper, J. R. Schaefer, C. Meissner, H. Kather, et al. Low Hepatic Lipase Activity Is a Novel Risk Factor for Coronary Artery Disease Circulation, December 18, 2001; 104(25): 3057 - 3062. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. von Eckardstein, J.-R. Nofer, and G. Assmann High Density Lipoproteins and Arteriosclerosis : Role of Cholesterol Efflux and Reverse Cholesterol Transport Arterioscler. Thromb. Vasc. Biol., January 1, 2001; 21(1): 13 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Foger, M. Chase, M. J. Amar, B. L. Vaisman, R. D. Shamburek, B. Paigen, J. Fruchart-Najib, J. A. Paiz, C. A. Koch, R. F. Hoyt, et al. Cholesteryl Ester Transfer Protein Corrects Dysfunctional High Density Lipoproteins and Reduces Aortic Atherosclerosis in Lecithin Cholesterol Acyltransferase Transgenic Mice J. Biol. Chem., December 24, 1999; 274(52): 36912 - 36920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Hirano, S. Yamashita, Y. Nakagawa, T. Ohya, F. Matsuura, K. Tsukamoto, Y. Okamoto, A. Matsuyama, K. Matsumoto, J.-i. Miyagawa, et al. Expression of Human Scavenger Receptor Class B Type I in Cultured Human Monocyte-Derived Macrophages and Atherosclerotic Lesions Circ. Res., July 9, 1999; 85(1): 108 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Plump, L. Masucci-Magoulas, C. Bruce, C. L. Bisgaier, J. L. Breslow, and A. R. Tall Increased Atherosclerosis in ApoE and LDL Receptor Gene Knock-Out Mice as a Result of Human Cholesteryl Ester Transfer Protein Transgene Expression Arterioscler. Thromb. Vasc. Biol., April 1, 1999; 19(4): 1105 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Chung, F. Franklin, B. H. S. Cho, J. P. Segrest, K. Hart, and B. E. Darnell Potencies of Lipoproteins in Fasting and Postprandial Plasma to Accept Additional Cholesterol Molecules Released From Cell Membranes Arterioscler. Thromb. Vasc. Biol., August 1, 1998; 18(8): 1217 - 1230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sasai, K. Okumura-Noji, T. Hibino, R. Ikeuchi, N. Sakuma, T. Fujinami, and S. Yokoyama Human cholesteryl ester transfer protein measured by enzyme-linked immunosorbent assay with two monoclonal antibodies against rabbit cholesteryl ester transfer protein: plasma cholesteryl ester transfer protein and lipoproteins among Japanese hypercholesterolemic patients Clin. Chem., July 1, 1998; 44(7): 1466 - 1473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sugano, N. Makino, S. Sawada, S. Otsuka, M. Watanabe, H. Okamoto, M. Kamada, and A. Mizushima Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits J. Biol. Chem., February 27, 1998; 273(9): 5033 - 5036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Fournier, J.-L. Paul, V. Atger, A. Cogny, T. Soni, M. de la Llera-Moya, G. Rothblat, and N. Moatti HDL Phospholipid Content and Composition as a Major Factor Determining Cholesterol Efflux Capacity From Fu5AH Cells to Human Serum Arterioscler. Thromb. Vasc. Biol., November 1, 1997; 17(11): 2685 - 2691. [Abstract] [Full Text]
|
|
|
|
|
|
H. C.F. Oliveira, L. Ma, R. Milne, S. M. Marcovina, A. Inazu, H. Mabuchi, and A. R. Tall Cholesteryl Ester Transfer Protein Activity Enhances Plasma Cholesteryl Ester Formation: Studies in CETP Transgenic Mice and Human Genetic CETP Deficiency Arterioscler. Thromb. Vasc. Biol., June 1, 1997; 17(6): 1045 - 1052. [Abstract] [Full Text]
|
|
|
|
|
|
K.-i. Hirano, S. Yamashita, N. Nakajima, T. Arai, T. Maruyama, Y. Yoshida, M. Ishigami, N. Sakai, K. Kameda-Takemura, and Y. Matsuzawa Genetic Cholesteryl Ester Transfer Protein Deficiency Is Extremely Frequent in the Omagari Area of Japan: Marked Hyperalphalipoproteinemia Caused by CETP Gene Mutation Is Not Associated With Longevity Arterioscler. Thromb. Vasc. Biol., June 1, 1997; 17(6): 1053 - 1059. [Abstract] [Full Text]
|
|
|
|
|
|
J. A. Kuivenhoven, P. de Knijff, J. M.A. Boer, H. A. Smalheer, G.-J. Botma, J. C. Seidell, J. J.P. Kastelein, and P. H. Pritchard Heterogeneity at the CETP Gene Locus : Influence on Plasma CETP Concentrations and HDL Cholesterol Levels Arterioscler. Thromb. Vasc. Biol., March 1, 1997; 17(3): 560 - 568. [Abstract] [Full Text]
|
|